Agios Pharma Drops Sickle Cell Disease Drug After Phase 2 Data Disappoint
Agios Pharmaceuticals said tebapivat fell short of expectations in a Phase 2 test in sickle cell disease.
Agios Pharmaceuticals
Agios Pharmaceuticals is a biopharmaceutical company focused on developing therapies for rare diseases, including pyruvate kinase (PK) activation and other cellular metabolism targets. The company markets PYRUKYND® (mitapivat) for hemolytic anemia in adults with PK deficiency and is exploring additional indications in thalassemia and sickle cell disease.
Company Info
Sector:Biopharmaceuticals
Headquarters:Cambridge, Massachusetts, United States
Founded:2007
Website:www.agios.com
Upcoming Milestones & Key Dates
Q3 2026
Earnings
PYRUKYND® Q2 sales update
H2 2026
Regulatory
Thalassemia regulatory interactions
Late 2026
Corporate
Pipeline expansion announcements
Clinical Development Pipeline
PYRUKYND® (mitapivat)
Target: Pyruvate kinase activatorMitapivat
Target: Pyruvate kinase activatorAG-946
Target: Pyruvate kinase activator (next-gen)Recent News
Agios scraps sickle cell drug
Agios scrapped its sickle cell drug tebapivat after disappointing Phase 2 data.
Agios axes next-gen sickle cell candidate after it fails to best Novo’s asset
Agios axes next-gen sickle cell candidate after it fails to best Novo’s asset.
Agios says adios to sickle cell program over lackluster Phase 2 data
Agios said adios to its sickle cell program over lackluster Phase 2 data.
Leadership Team
Brian Goff
Chief Executive Officer
Cecilia Jones
Chief Financial Officer
Sarah Gheuens
Chief Medical Officer
Careers & Job Openings